BioAgilytix to acquire Australia-based 360biolabs® and US-based MicroConstants, to advance its global expansion

Posted: 19 Aug 2021

London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company, BioAgilytix, regarding the acquisitions of 360biolabs® and MicroConstants.

BioAgilytix Labs, LLC (‘BioAgilytix’), a leading global Contract Research Laboratory, recently announced that it has acquired 360biolabs®, the most comprehensive Contract Research Organization in Australia and MicroConstants, the US-based industry leading bioanalytical service provider.

Located in Australia’s biomedical and clinical research hub, 360biolabs offers world-class virology and immunology expertise, with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities with a state-of-the-art flow cytometry suite, molecular biology PCR suite and expansive bioanalytical LC-MS/MS small molecule capabilities. The transaction will expand BioAgilytix’s global footprint into jurisdictions of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adding further capacity by joining 360biolabs’ internationally recognised Quality systems (ISO/IEC 17025, ISO 15189, GLP and GCLP). “This planned acquisition is part of our strategic growth strategy to expand our capacity, expertise and agility to serve customers across all geographies, and we look forward to welcoming the 360biolabs team and integrating the business. Joining forces makes sense for our two organizations, but most importantly for our combined clients and the patients they serve.” said Jim Datin, Preseident and CEO of BioAgilytix.

MicroConstants, to be known as BioAgilytix San Diego, provides industry-leading services in method development, validation, and sample analysis for small and large molecule therapeutics and biomarkers. The business has deep expertise in bioanalytical testing services with over 20 years of experience and will complement BioAgilytix’s already impressive contract research services for the pharmaceutical and biotech industry. MicroConstants China remains a separate business entity and does not form part of this transaction. “We are excited to welcome the MicroConstants team to BioAgilytix and to work with them to integrate the business. We believe that by joining forces, BioAgilytix and MicroConstants will not only create significant scientific and performance synergies, but also we are better able to serve the growing biotechnology community on the West Coast.” said Jim Datin.

The 360biolabs acquisition is subject to Australian Foreign Investment Review Board (“FIRB”) requirements and receipt of FIRB approval. The acquisition is expected to close in the Q3.

Further information:
GHO Capital Partners LLP
T +44 20 3700 7440
[email protected]

About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit

About BioAgilytix
BioAgilytix is a leading bioanalytical testing laboratory specialising in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle Park, the Cambridge area of Massachusetts, and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states.
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.). BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For further information, visit

About 360biolabs®
360biolabs® is the leading and most comprehensive specialty laboratory in the Australia & New Zealand region. Our expert pharmacokinetic (PK) and pharmacodynamic (PD) assay services support small molecule, biologic, vaccine and other innovative therapeutic solutions to human health. A world class and industry experienced technical team, known for their ability to successfully deliver technically challenging assays, 360biolabs® supports global Pharmaceutical and biotech companies in a diverse and growing range of therapeutics areas.
360biolabs® delivers global regulatory compliant assays and reports following ISO/IEC 17025, ISO 15189, OECD GLP, GCLP and ICH GCP with a focus on quality. For further information, visit

About MicroConstants Inc.
MicroConstants Inc., is one of the largest bioanalytical LC/MS/MS service providers in the United States, with headquarters in San Diego, California for over 20 years.  MicroConstants helps its clients develop novel therapeutics by supporting clinical and preclinical regulated bioanalysis studies. Since 1998, MicroConstants has supported 290+ clients in 45 countries, completed over 8,200 projects, and developed more than 2,400 methods. For more information on how MicroConstants fulfills its purpose, please visit